ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Thoughtful Pediatric Care: Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

Thomas R. Collins  |  March 9, 2020

In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…

Filed under:Conditions Tagged with:2019 ACR/ARP Annual Meetingpediatric arthritisPediatric RheumatologyPediatrics

Physicians Identify Professional Dissonance as a Cause of Burnout

Lara C. Pullen, PhD  |  March 9, 2020

Recent research into burnout in primary care providers has found many providers experience professional dissonance and cite increasing paperwork and undervaluation as contributors to burnout. The study also outlined solutions that may improve professional fulfillment…

Filed under:Career DevelopmentProfessional Topics Tagged with:burnoutphysician burnoutprimary carePrimary Care Physicianwork-life balance

Dr. Caplan turned 106 on Nov. 21 and remains physically and mentally active.

Paul S. Caplan, MD: A Physician’s Journey

The Medical Alumni Association at the University of Pittsburgh  |  March 8, 2020

Editor’s note: It is with much sadness that we learned this morning that Paul Caplan, MD, passed away yesterday, March 7, 2020. “He was a remarkable person who continued to celebrate life up to the end,” says Terence W. Starz, MD, University of Pittsburgh School of Medicine. “He had a great caring, wisdom, and commitment…

Filed under:Profiles Tagged with:Dr. Paul S. Caplan

The ACR Introduces New Reproductive Health Guideline

Susan Bernstein  |  March 4, 2020

The evidence-based guideline includes contraceptive recommendations and suggestions for rheumatologists co-managing patients with obstetrician-gynecologists and other specialists.

Filed under:Clinical Criteria/Guidelines Tagged with:Clinical GuidelinesEliza ChakravartyLisa R. SammaritanoMDMSreproductive health

Sports Doctors May Accidentally Prescribe Banned Steroids

Lisa Rapaport  |  March 4, 2020

(Reuters Health)—Sports physicians routinely prescribe corticosteroids to athletes for conditions, such as inflammation, asthma and allergies, but not all of them know which forms of these drugs are banned under anti-doping rules, a study suggests. The survey of 603 physicians from 30 countries found four in five prescribe oral corticosteroids to athletes, one of the…

Filed under:Drug Updates

Phase 3 Results for Olokizumab in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  March 3, 2020

In a recent study, olokizumab proved safe and effective for treating the signs and symptoms of RA and improving patients’ physical function…

Filed under:Drug Updates Tagged with:2019 ACR/ARP Annual MeetingolokizumabRheumatoid Arthritis (RA)

Pearls & Myths: Experts Offer Advice & Dispel Myths

Thomas R. Collins  |  February 25, 2020

GCA, GPA, myositis, new research—rheumatology care keeps clinicians on their toes & requires them to stay up to date…

Filed under:CareerCareer DevelopmentMeeting ReportsProfessional Topics Tagged with:2019 ACR/ARP Annual Meeting

Can Lupus Be Prevented? Research Reveals Clues to Who’s Most Likely to Transition to Classified Disease

Susan Bernstein  |  February 25, 2020

How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:2019 ACR/ARP Annual Meetingenvironmental factorgeneticSLEsystemic lupus erythematosus (SLE)

Low-Dose Methotrexate Can Cause Adverse Effects

Will Boggs, MD  |  February 19, 2020

NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…

Filed under:Drug Updates Tagged with:adverse eventsMethotrexate

FDA Advisory Committees Reject Oxycodegol (NKTR-181) Application

Michele B. Kaufman, PharmD, BCGP  |  February 19, 2020

FDA advisory committees rejected the new drug application for oxycodegol, an opioid analgesic, due to a lack of data regarding it’s potential for abuse…

Filed under:AnalgesicsDrug Updates Tagged with:FDANKTR-181opioidoxycodegolPain ManagementU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 111
  • 112
  • 113
  • 114
  • 115
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences